Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial

被引：5

作者：

Briones, Javier ^{[1
]}

Novelli, Silvana ^{[1
]}

Garcia-Marco, Jose A. ^{[2
]}

Tomas, Jose F. ^{[3
]}

Bernal, Teresa ^{[4
]}

Grande, Carlos ^{[5
]}

Canales, Miguel A. ^{[6
]}

Torres, Antonio ^{[7
]}

Moraleda, Jose M. ^{[8
]}

Panizo, Carlos ^{[9
]}

Jarque, Isidro ^{[10
]}

Palmero, Francisca ^{[11
]}

Hernandez, Miguel ^{[12
]}

Gonzalez-Barca, Eva ^{[13
]}

Lopez, Dulce ^{[1
]}

Caballero, Dolores ^{[14
]}

机构：

[1] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[2] Hosp Univ Puerta de Hierro, Madrid, Spain

[3] MD Anderson Int, Madrid, Spain

[4] Hosp Univ Cent Asturias, Oviedo, Spain

[5] Hosp 12 Octubre, E-28041 Madrid, Spain

[6] Hosp La Paz, Madrid, Spain

[7] Hosp Reina Sofia, Cordoba, Spain

[8] Hosp Virgen Arrixaca, Murcia, Spain

[9] Univ Navarra Clin, Pamplona, Spain

[10] Hosp Univ La Fe, Valencia, Spain

[11] Hosp Univ Alicante, Alicante, Spain

[12] Hosp Univ Canarias, Tenerife, Spain

[13] ICO Duran & Reynals, Barcelona, Spain

[14] Hosp Univ Salamanca, Salamanca, Spain

来源：

HAEMATOLOGICA | 2014年 / 99卷 / 07期

关键词：

diffuse large B-cell lymphoma; ibritumomab tiuxetan; autologous transplantation; relapse;

D O I：

10.3324/haematol.2014.108308

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：1

共 50 条

[1] Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial
Briones, Javier
Novelli, Silvana
Garcia-Marco, Jose A.
Tomas, Jose F.
Bernal, Teresa
Grande, Carlos
Canales, Miguel A.
Torres, Antonio
Moraleda, Jose M.
Panizo, Carlos
Jarque, Isidro
Palmero, Francisca
Hernandez, Miguel
Gonzalez-Barca, Eva
Lopez, Dulce
Caballero, Dolores
HAEMATOLOGICA, 2014, 99 (03) : 505 - 510
[2] Autologous Stem Cell Transplantation with Yttriumm-90-Ibritumomab Tiuxetan (Zevalin) Plus BEAM Conditioning in Patients with Refractory Non-Hodgkin Diffuse Large B-Cell Lymphoma: Results of a Prospective, Multicenter, Phase II Clinical Trial
Briones, Javier
Novelli, Silvana
Garcia Marco, Jose Antonio
Francisco Tomas, Jose
Bernal, Teresa
Grande, Carlos
Canales, Miguel
Torres, Antonio
Moraleda, Jose M.
Panizo, Carlos
Palmero, Fernanda
Jarque, Isidro
Hernandez, Miguel
Gonzalez Barca, Eva
Lopez, Dulce
Caballero, Dolores
BLOOD, 2012, 120 (21)
[3] Comparison between BEAM and Yttrium-90 Ibritumomab Tiuxetan (Zevalin)-BEAM as conditioning regimen before autologous stem cell transplantation in patients with non-Hodgkin B-Cell Lymphoma
Chic Acevedo, C.
Garcia Torres, E.
Llamas Poyato, M. J.
Rodriguez, G.
Martin, C.
Rojas, R.
Serrano, J.
Tabares, S.
Vallejo, J. A.
Sanchez, J.
BONE MARROW TRANSPLANTATION, 2015, 50 : S224 - S224
[4] Yttrium-90 ibritumomab tiuxetan combined with high-dose beam chemotherapy and autologous stem cell transplantation for relapsed/refractory B-cell non-Hodgkin's lymphoma
Shimabukuro-Vornhagen, A.
Josting, A.
Scheid, C.
Huebel, K.
Boldt, F.
Dietlein, M.
Engert, A.
Schnell, R.
ANNALS OF ONCOLOGY, 2008, 19 : 241 - 242
[5] Yttrium-90 ibritumomab tiuxetan combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for relapsed/refractory B-cell non-Hodgkin's lymphoma
Shimabukuro-Vornhagen, A.
Josting, A.
Huebel, K.
Scheid, C.
Dietlein, M.
Engert, A.
Schnell, R.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[6] Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed/refractory diffuse large B-Cell lymphoma not appropriate for autologous stem cell transplantation: Results of an open-label phase II trial.
Morschhauser, F
Huglo, D
Martinelli, G
Paganelli, G
Zinzani, PL
Hadjiyiannakis, D
Liberati, A
Illidge, T
Milpied, N
Stein, H
Kalmus, J
Morel, P
Reimann, U
Marcus, R
BLOOD, 2004, 104 (11) : 41A - 41A
[7] Autologous Transplantation for Transformed Non-Hodgkin Lymphoma Using an Yttrium-90 Ibritumomab Tiuxetan Conditioning Regimen
Mei, Matthew
Wondergem, Marielle J.
Palmer, Joycelynne M.
Shimoni, Avichai
Hasenkamp, Justin
Tsai, Ni-Chun
Simpson, Jennifer
Nademanee, Auayporn
Raubitschek, Andrew
Forman, Stephen J.
Krishnan, Amrita Y.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (12) : 2072 - 2075
[8] Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma
Shah, Jatin
Wang, Wenquan
Harrough, V. Douglas
Saville, Wayne
Meredith, Ruby
Shen, Sui
Mueh, John
Li, John
Jasthy, Sri
Maggass, Gregory
Mckay, Charles
Krumdieck, Richard
Tharp, Morgan
Winter, Christine
Gregory, Stephanie
Buchholz, William
Awasthi, Sanjay
Jacobs, Samuel
Chung, Harold
Egner, James
Lobuglio, Albert F.
Forero, Andres
LEUKEMIA & LYMPHOMA, 2007, 48 (09) : 1736 - 1744
[9] Phase I trial of yttrium 90 ibritumomab tiuxetan (90Y-RIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL)
Swinnen, L. J.
Flinn, I. W.
Kahl, B. S.
Frey, E.
Rogers, K.
Jung, M.
Jacene, H.
Wahl, R. L.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[10] Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphorna not appropriate for autologous stem-cell transplantation
Morschhauser, Franck
Illidge, Tim
Huglo, Damien
Martinelli, Giovanni
Paganelli, Giovanni
Zinzani, Pier Luigi
Rule, Simon
Liberati, Anna Marina
Milpied, Noel
Hess, Georg
Stein, Harald
Kalmus, Joachim
Marcus, Robert
BLOOD, 2007, 110 (01) : 54 - 58

← 1 2 3 4 5 →